+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opium (Opioid) Addiction - Pipeline Review, H2 2019

  • ID: 4866524
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 133 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adapt Pharma Ltd
  • Aphios Corp
  • Emerald Bioscience Inc
  • iX Biopharma Ltd
  • Orexigen Therapeutics Inc
  • Phoenix PharmaLabs Inc
  • MORE
Opium (Opioid) Addiction - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2019, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 1, 24, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 5 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adapt Pharma Ltd
  • Aphios Corp
  • Emerald Bioscience Inc
  • iX Biopharma Ltd
  • Orexigen Therapeutics Inc
  • Phoenix PharmaLabs Inc
  • MORE
Introduction
Opium (Opioid) Addiction - Overview
Opium (Opioid) Addiction - Therapeutics Development
Opium (Opioid) Addiction - Therapeutics Assessment
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
Opium (Opioid) Addiction - Drug Profiles
Opium (Opioid) Addiction - Dormant Projects
Opium (Opioid) Addiction - Discontinued Products
Opium (Opioid) Addiction - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Opium (Opioid) Addiction, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Opium (Opioid) Addiction - Pipeline by Adapt Pharma Ltd, H2 2019
Table 13: Opium (Opioid) Addiction - Pipeline by Adial Pharmaceuticals Inc, H2 2019
Table 14: Opium (Opioid) Addiction - Pipeline by Alar Pharmaceuticals Inc, H2 2019
Table 15: Opium (Opioid) Addiction - Pipeline by Amygdala Neurosciences Inc, H2 2019
Table 16: Opium (Opioid) Addiction - Pipeline by Antheia Inc, H2 2019
Table 17: Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
Table 18: Opium (Opioid) Addiction - Pipeline by Aphios Corp, H2 2019
Table 19: Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc, H2 2019
Table 20: Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2019
Table 21: Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H2 2019
Table 22: Opium (Opioid) Addiction - Pipeline by BioXcel Therapeutics Inc, H2 2019
Table 23: Opium (Opioid) Addiction - Pipeline by Cessation Therapeutics LLC, H2 2019
Table 24: Opium (Opioid) Addiction - Pipeline by Delpor Inc, H2 2019
Table 25: Opium (Opioid) Addiction - Pipeline by Emerald Bioscience Inc, H2 2019
Table 26: Opium (Opioid) Addiction - Pipeline by Fab’entech SA, H2 2019
Table 27: Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2019
Table 28: Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H2 2019
Table 29: Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H2 2019
Table 30: Opium (Opioid) Addiction - Pipeline by Mind Medicine Inc, H2 2019
Table 31: Opium (Opioid) Addiction - Pipeline by Nirsum Laboratories Inc, H2 2019
Table 32: Opium (Opioid) Addiction - Pipeline by Omeros Corp, H2 2019
Table 33: Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2019
Table 34: Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2019
Table 35: Opium (Opioid) Addiction - Pipeline by Orexo AB, H2 2019
Table 36: Opium (Opioid) Addiction - Pipeline by Osmotica Pharmaceutical Corp, H2 2019
Table 37: Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H2 2019
Table 38: Opium (Opioid) Addiction - Pipeline by Pharmazz Inc, H2 2019
Table 39: Opium (Opioid) Addiction - Pipeline by Phoenix PharmaLabs Inc, H2 2019
Table 40: Opium (Opioid) Addiction - Pipeline by Plumb Pharmaceuticals LLC, H2 2019
Table 41: Opium (Opioid) Addiction - Pipeline by Serina Therapeutics Inc, H2 2019
Table 42: Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, H2 2019
Table 43: Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H2 2019
Table 44: Opium (Opioid) Addiction - Pipeline by Trevena Inc, H2 2019
Table 45: Opium (Opioid) Addiction - Pipeline by Vivera Pharmaceuticals Inc, H2 2019
Table 46: Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2019
Table 47: Opium (Opioid) Addiction - Dormant Projects, H2 2019
Table 48: Opium (Opioid) Addiction - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 49: Opium (Opioid) Addiction - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Opium (Opioid) Addiction, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adapt Pharma Ltd
  • Adial Pharmaceuticals Inc
  • Alar Pharmaceuticals Inc
  • Amygdala Neurosciences Inc
  • Antheia Inc
  • Aoxing Pharmaceutical Company Inc
  • Aphios Corp
  • Aquilus Pharmaceuticals Inc
  • BioCorRx Inc
  • BioDelivery Sciences International Inc
  • BioXcel Therapeutics Inc
  • Cessation Therapeutics LLC
  • Delpor Inc
  • Emerald Bioscience Inc
  • Fab’entech SA
  • Indivior Plc
  • Insys Therapeutics Inc
  • iX Biopharma Ltd
  • Mind Medicine Inc
  • Nirsum Laboratories Inc
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • Orexo AB
  • Osmotica Pharmaceutical Corp
  • Pfizer Inc
  • Pharmazz Inc
  • Phoenix PharmaLabs Inc
  • Plumb Pharmaceuticals LLC
  • Serina Therapeutics Inc
  • Syntropharma Ltd
  • Titan Pharmaceuticals Inc
  • Trevena Inc
  • Vivera Pharmaceuticals Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll